Scarica l'app Stockscreener
29.46
1.97%
0.57
Dopo l'orario di chiusura:
29.46
Urogen Pharma Ltd Borsa (URGN) Ultime notizie
How UGN-103’s Phase 3 Data and NDA Timeline Could Reshape UroGen Pharma (URGN) Investors’ Outlook - simplywall.st
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge - AOL.com
How UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) Investors - Yahoo Finance
URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Sector Update: Health Care - Moomoo
UroGen Pharma Investor Event Reinforced Zusduri Commercial Thesis, Oppenheimer Says - marketscreener.com
Oppenheimer reiterates Outperform on UroGen Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates UroGen Pharma stock rating on durability data - Investing.com India
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA - GuruFocus
H.C. Wainwright reiterates UroGen Pharma stock rating on durability data By Investing.com - Investing.com South Africa
URGN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
UroGen Pharma Price Target Maintained With a $45.00/Share by HC Wainwright & Co. - Moomoo
A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data - simplywall.st
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story - simplywall.st
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC - Sahm
UroGen’s UGN-103 shows 94.5% response durability in trial By Investing.com - Investing.com Australia
Why (URGN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
UroGen Pharma (URGN) Reports Strong Results for UGN-103 in Bladd - GuruFocus
Paradigm reports 1.7M-share stake in UroGen (URGN) in 13G/A - Stock Titan
UroGen Moves Toward FDA Filing For UGN-103 - Citeline News & Insights
TD Bank subsidiary reports 2.62M UroGen shares (URGN) — 5.4% - Stock Titan
UroGen’s UGN-103 shows 94.5% response durability in trial - Investing.com UK
UroGen Reports 94.5% Six-Month Duration of Response in - GlobeNewswire
Bladder cancer drug posts 94.5% 6-month response, heads for 2026 FDA filing - Stock Titan
UroGen reports 64.5% event-free rate at three years for bladder cancer drug By Investing.com - Investing.com India
URGN: Caribou's allogeneic CAR T therapies show best-in-class potential with pivotal trials advancing - TradingView
UroGen Pharma (URGN) Reports Positive Long-Term Response Data fo - GuruFocus
UroGen Pharma Says ZUSDURI Shows Durable Disease-Free Outcomes at Three Years - Moomoo
UroGen reports 64.5% event-free rate at three years for bladder cancer drug - Investing.com
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial - The Manila Times
Urogen Pharma LtdReports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial - TradingView
ZUSDURI Median Duration of Response Still Not Reached with - GlobeNewswire
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $45 - 富途牛牛
MSN Money - MSN
Earnings call transcript: UroGen Pharma beats Q1 2026 EPS forecast - Investing.com India
Earnings call transcript: UroGen Pharma beats Q1 2026 EPS forecast By Investing.com - Investing.com Nigeria
UroGen Pharma stock (IL0011408896): CMO sells 10K shares at $30 - AD HOC NEWS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):